Price
$0.38
Decreased by -0.80%
Dollar volume (20D)
214.37 K
ADR%
9.48
Earnings report date
Aug 7, 2025
Shares float
45.15 M
Shares short
4.13 M [9.14%]
Shares outstanding
58.42 M
Market cap
22.58 M
Beta
0.91
Price/earnings
N/A
20D range
0.36 0.48
50D range
0.36 0.58
200D range
0.24 2.52

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer.

The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and squamous cell carcinoma of head and neck.

It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3.

The company was founded in 2007 and is headquartered in San Diego, California.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
May 12, 25 -0.26
Increased by +45.83%
-0.29
Increased by +11.35%
Mar 24, 25 -0.30
Increased by +46.49%
-0.38
Increased by +21.05%
Nov 7, 24 -0.22
Increased by +68.57%
-0.36
Increased by +38.89%
Aug 8, 24 -0.44
Increased by +41.33%
-0.44
May 14, 24 -0.48
Increased by +17.24%
-0.54
Increased by +11.11%
Mar 26, 24 -0.56
Increased by +11.02%
-0.79
Increased by +29.04%
Nov 7, 23 -0.70
Decreased by -1.45%
-0.80
Increased by +12.50%
Aug 1, 23 -0.75
Increased by +2.60%
-0.64
Decreased by -17.19%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Mar 31, 25 0.00
Decreased by N/A%
-15.33 M
Increased by +34.00%
Decreased by N/A%
Decreased by N/A%
Dec 31, 24 0.00
Decreased by -100.00%
-14.88 M
Increased by +44.72%
Decreased by N/A%
Decreased by N/A%
Sep 30, 24 11.00 M
Increased by +N/A%
-10.59 M
Increased by +68.23%
Decreased by -96.24%
Decreased by N/A%
Jun 30, 24 0.00
Decreased by N/A%
-21.07 M
Increased by +41.06%
Decreased by N/A%
Decreased by N/A%
Mar 31, 24 0.00
Decreased by N/A%
-23.23 M
Increased by +10.60%
Decreased by N/A%
Decreased by N/A%
Dec 31, 23 1.71 M
Increased by +N/A%
-26.93 M
Increased by +3.01%
Decreased by -1.58 K%
Decreased by N/A%
Sep 30, 23 0.00
Decreased by N/A%
-33.33 M
Decreased by -31.15%
Decreased by N/A%
Decreased by N/A%
Jun 30, 23 0.00
Decreased by N/A%
-35.75 M
Decreased by -24.31%
Decreased by N/A%
Decreased by N/A%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY